Syndax Pharmaceuticals Issues New Inducement Grants Amidst Ongoing Cancer Treatment Development Syndax Pharmaceuticals has announced the granting of stock options to new employees as part of its 2023 Inducement Plan, enhancing its cancer therapies pipeline.

Syndax Pharmaceuticals Issues New Inducement Grants Amidst Ongoing Cancer Treatment Development #United_States #cancer_therapies #Waltham #Syndax_Pharmaceuticals #SNDX

Syndax Pharmaceuticals Shares 2024 Achievements and Future Goals at J.P. Morgan Healthcare Conference Syndax reveals its significant accomplishments in 2024 at the J.P. Morgan Healthcare Conference, focusing on groundbreaking therapies and future milestones.

Syndax Pharmaceuticals Shares 2024 Achievements and Future Goals at J.P. Morgan Healthcare Conference #USA #Waltham #Syndax_Pharmaceuticals #Revuforj #Niktimvo

Kuehn Law is Urging Investors of Syndax Pharmaceuticals to Engage with Their Legal Services Kuehn Law is investigating potential breaches of fiduciary duty by Syndax Pharmaceuticals' officers. Shareholders may have claims for damages and governance reforms.

Kuehn Law is Urging Investors of Syndax Pharmaceuticals to Engage with Their Legal Services #United_States #New_York #Investor_Rights #Kuehn_Law #Syndax_Pharmaceuticals

Syndax Pharmaceuticals Announces Inducement Grants for New Employees In Accordance with NASDAQ Listing Rules Syndax Pharmaceuticals has announced the granting of inducement awards for new employees under NASDAQ rules, signaling growth in cancer therapy development.

Syndax Pharmaceuticals Announces Inducement Grants for New Employees In Accordance with NASDAQ Listing Rules #United_States #Waltham #Syndax_Pharmaceuticals #Revuforj #Niktimvo

Investigation Launched into Syndax Pharmaceuticals Over Possible Board Misconduct Purcell & Lefkowitz LLP is closely examining Syndax Pharmaceuticals for potential breaches of fiduciary duty by its board directors. Shareholders encouraged to learn more.

Investigation Launched into Syndax Pharmaceuticals Over Possible Board Misconduct #United_States #New_York #Fiduciary_Duty #Syndax_Pharmaceuticals #Purcell_&_Lefkowitz

Syndax Pharmaceuticals Releases Positive Outcomes for Revuforj from Recent Trials in AML Research Syndax Pharmaceuticals reveals encouraging data for Revuforj® in treating relapsed or refractory acute myeloid leukemia, marking a significant milestone in cancer therapy.

Syndax Pharmaceuticals Releases Positive Outcomes for Revuforj from Recent Trials in AML Research #USA #Waltham #Syndax_Pharmaceuticals #Revuforj #AML_Trials

Syndax Pharmaceuticals Announces Grants of Stock Options for New Employees as Inducement Awards Syndax Pharmaceuticals has reported inducement grants under NASDAQ Rule 5635(c)(4), awarding stock options to new hires, reinforcing its commitment to innovation.

Syndax Pharmaceuticals Announces Grants of Stock Options for New Employees as Inducement Awards #United_States #Waltham #Syndax_Pharmaceuticals #Revuforj #Niktimvo

Syndax Pharmaceuticals Discusses Innovative Cancer Therapies at Citi 2024 Healthcare Conference Syndax Pharmaceuticals will engage in a panel on oncology mechanisms at the Citi 2024 Conference, highlighting breakthroughs in cancer therapy.

Syndax Pharmaceuticals Discusses Innovative Cancer Therapies at Citi 2024 Healthcare Conference #USA #Waltham #Syndax_Pharmaceuticals #avodart #Revuforj